Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S396000, C548S300100, C548S311100, C548S262200
Reexamination Certificate
active
07863309
ABSTRACT:
In one aspect, the invention relates to compounds having the formula:wherein: Ar, r, Z, X, R3, and R5-7are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
REFERENCES:
patent: 4513009 (1985-04-01), Roques et al.
patent: 4610816 (1986-09-01), Berger
patent: 4722810 (1988-02-01), Delaney et al.
patent: 4929641 (1990-05-01), Haslanger et al.
patent: 5030654 (1991-07-01), Barnish et al.
patent: 5138069 (1992-08-01), Carini et al.
patent: 5155100 (1992-10-01), Erion et al.
patent: 5217996 (1993-06-01), Ksander
patent: 5270317 (1993-12-01), Bernhart et al.
patent: 5294632 (1994-03-01), Erion et al.
patent: 5399578 (1995-03-01), Buhlmayer et al.
patent: 5444081 (1995-08-01), Gleason et al.
patent: 5508272 (1996-04-01), Robl
patent: 5587375 (1996-12-01), Robl
patent: 5591762 (1997-01-01), Hauel et al.
patent: 5616599 (1997-04-01), Yanagisawa et al.
patent: 5705517 (1998-01-01), Naka et al.
patent: 5864043 (1999-01-01), Narr et al.
patent: 6090828 (2000-07-01), Reitz
patent: 6602866 (2003-08-01), Flynn et al.
patent: 6777443 (2004-08-01), Fink
patent: 6852745 (2005-02-01), Murugesan et al.
patent: 7060721 (2006-06-01), Oku et al.
patent: 2003/0144215 (2003-07-01), Ksander et al.
patent: 2004/0048911 (2004-03-01), Reitz et al.
patent: 2006/0046978 (2006-03-01), Pierau et al.
patent: 2008/0188533 (2008-08-01), Choi et al.
patent: 2008/0269305 (2008-10-01), Allegretti et al.
patent: 2008/0318951 (2008-12-01), Allegretti et al.
patent: 2009/0023228 (2009-01-01), Allegretti et al.
patent: 2009/0093417 (2009-04-01), Choi et al.
patent: 0 361 365 (1990-04-01), None
patent: 0 437 103 (1991-07-01), None
patent: 0 505 954 (1992-09-01), None
patent: 0 726 072 (1996-08-01), None
patent: 06 184086 (1994-07-01), None
patent: 07 048360 (1995-02-01), None
patent: 2003 048874 (2003-02-01), None
patent: WO 92/13564 (1992-08-01), None
patent: WO 00/1389 (2000-01-01), None
patent: WO 2006/027680 (2006-03-01), None
patent: WO 2006/086456 (2006-08-01), None
patent: WO 2007/045663 (2007-04-01), None
patent: WO 2007/056546 (2007-05-01), None
patent: WO 2007/106708 (2007-09-01), None
patent: WO 2007/109456 (2007-09-01), None
patent: 2008133896 (2008-11-01), None
patent: WO 2008/142576 (2008-11-01), None
Ashton et al., “Nonpeptide Angiotensin II Antagonists Derived from 4H-1,2,4-triazoles and 3H-Imidazo[1,2-b][1,2,4] triazoles”, J. Med. Chem., 36, 591-609 (1993).
Notification of Transmittal of the International Search Report and The Written Opinion of the International Searching Authority, or the Declaration for PCT/US2009/051507.
U.S. Appl. No. 12/330,289, Choi et al.
U.S. Appl. No. 12/431,056, Allegretti et al.
Fournie-Zaluski et al., “Design of Orally Active Dual Inhibitors of Neutral Endopeptidase and Angiotensin-Converting Enzyme with long Duration of Action”Journal of Medicinal Chemistry39:2594-2608 (1996).
Gardiner et al., “Regional hemodynamic effects of neutral endopeptidase inhibition and angiotensin (AT1) receptor antagonism alone or in combination in conscious spontaneously hypertensive rats”, The Journal of Pharmacology and Experimental Therapeutics, vol. 319 No. 1, pp. 340-348 (2006).
Middlemiss et al., “Benzofuran based angiotensin II antagonists related to GR117289: Part II; amino acid amides”, Bioorganic & Medicinal Chemistry Letters, vol. 3, No. 10, pp. 2043-2046 (1993).
Pu et al., “The effect of combined AT1 receptor antagonist and neutral endopeptidase (NEP) inhibitor compared to the dual angiotensin converting enzyme inhibitor/NEP on endothelial function and vascular remodeling of SHRSP”, Abstract presented at the Canadian Cardiovascular Congress (Oct. 2004).
Robl et al., “Recent advances in the design and development of vasopeptidase inhibitors”, Expert Opinion on Therapeutic Patents, 9(12), pp. 1665-1677 (1999).
Shah et al., “Angiotensin II—AT1Receptor Antagonist: design, synthesis and evaluation of substituted carboxamido benzoimidazole derivatives”,European Journal of Medicinal Chemistry, 43(9), pp. 1808-1812 (2008).
Blair Brooke
Choi Seok-Ki
Fatheree Paul R.
Gendron Roland
McKinnell Robert Murray
Eberle Shelley
Hagenah Jeffrey A.
Saeed Kamal A
Shterengarts Samantha L
Theravance Inc.
LandOfFree
Dual-acting antihypertensive agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dual-acting antihypertensive agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dual-acting antihypertensive agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2702385